真题
已掌握 0/9
正在载入 PDF…
Slides版权归任课教师所有
1

The discipline and the discovery chain

学科定义与研发链条
1.1

Medicinal chemistry and the discovery process 药物化学与药物发现流程

本节覆盖 slides 6–9

A discipline at the intersection of chemistry and pharmacology, involved with designing, synthesizing and developing pharmaceutical drugs. It also studies existing drugs, their biological properties, and quantitative structure-activity relationships (QSAR). p.6 药物化学是处于化学与药理学交叉点的学科,从事药物的设计、合成与开发。它也研究已有药物、其生物学性质以及定量构效关系(QSAR)。

Core stages: discovery (hit-to-lead and lead optimization), synthetic chemistry and structural analysis, then development. Hit-to-lead and lead optimization are the chemistry-driven front end of the pipeline. p.7 核心阶段:发现(从苗头到先导 hit-to-lead 及先导优化)、合成化学与结构分析,随后进入开发。从苗头到先导及先导优化是流程中由化学驱动的前端环节。

1) Select disease — choose a disease area prioritizing unmet medical need. 2) Identify targets — pinpoint proteins, enzymes or DNA involved in the molecular mechanism. p.8 1)选择疾病:聚焦存在未满足医疗需求的疾病领域。2)确定靶点:定位参与分子机制的蛋白、酶或 DNA。

3) Synthesize ligands — design novel small molecules that selectively bind the target with high affinity and specificity. 4) Assess function — test activity, efficacy and safety in vitro and in vivo. p.8 3)合成配体:设计能以高亲和力和特异性选择性结合靶点的新型小分子。4)评估功能:通过体外和体内实验测试活性、疗效与安全性。

Disease level: epidemiology (distribution, prevalence, risk factors) plus causes and pathology (etiology and tissue alterations). System/cell level: mechanisms driving disease, molecular signaling pathways and immune responses. p.9 疾病层面:流行病学(分布、患病率、风险因素)以及病因与病理(病原学和组织改变)。系统/细胞层面:驱动疾病的机制、分子信号通路与免疫应答。

Molecular target level: the molecule's cellular role and the key binding (therapeutic) sites for drug development. p.9 分子靶点层面:分子在细胞中的作用,以及药物开发的关键结合(治疗)位点。

Medicinal chemistry and the discovery process Generated by GPT-Image-2.6 Sunburst
药物化学与药物发现流程 Medicinal chemistry and the discovery process
Resit 2023-24 · Q5
2

Drug targets

药物靶点
2.1

From target space to target classes 从靶点空间到靶点类型

本节覆盖 slides 10–11

All existing drugs act on fewer than ~500 known targets; genomics is expected to reveal 5,000–10,000 novel targets. p.10 现有全部药物作用于不到约 500 个已知靶点;基因组学预计可揭示 5,000–10,000 个新靶点。

Major small-molecule target families: enzymes, GPCRs, ion channels, transporters, nuclear receptors and kinases. ChEMBL research vs. approved-drug data show target popularity differs between research effort and clinical approval. p.10 主要小分子靶点家族:酶、G 蛋白偶联受体(GPCR)、离子通道、转运蛋白、核受体和激酶。ChEMBL 研究数据与获批药物数据显示,研究热度与临床获批在靶点分布上并不相同。

Proteins: receptors, enzymes, transport proteins, and structural proteins (e.g. tubulin). Other targets: lipids (cell membrane lipids), nucleic acids (DNA, RNA), and carbohydrates (cell-surface carbohydrates, antigens/recognition molecules). p.11 蛋白质:受体、酶、转运蛋白和结构蛋白(如微管蛋白 tubulin)。其他靶点:脂质(细胞膜脂质)、核酸(DNA、RNA)和糖类(细胞表面糖类、抗原与识别分子)。

From target space to target classes Generated by GPT-Image-2.6 Sunburst
从靶点空间到靶点类型 From target space to target classes
Final 2023-24 · Q3
3

Drug–target interactions

药物–靶点相互作用
3.1

Binding reversibility 结合的可逆性

本节覆盖 slides 12–13

Small molecules interact with specific amino acids in the target protein, or with bases in DNA. These interactions are studied computationally through molecular docking and molecular dynamics. p.12 小分子与靶蛋白中特定的氨基酸、或 DNA 中的碱基相互作用。这些相互作用可通过分子对接(molecular docking)和分子动力学(molecular dynamics)进行计算研究。

Irreversible: covalent bonding. Reversible (non-covalent): ionic, van der Waals, dipole-dipole, ion-dipole, hydrogen bonding, hydrophobic, π–π interactions, and desolvation penalties. p.13 不可逆作用:共价键。可逆(非共价)作用:离子、范德华、偶极-偶极、离子-偶极、氢键、疏水、π-π 相互作用以及去溶剂化惩罚。

Reversible ligands associate and dissociate. Covalent attachment can prolong target engagement. Generated by GPT-Image-2.6 Sunburst
可逆配体可以结合与解离。共价连接可延长对靶标的占据。 Reversible ligands associate and dissociate. Covalent attachment can prolong target engagement.
3.2

Non-covalent forces 非共价作用力

本节覆盖 slides 14–18

Electrostatic interactions between two charged molecules. Strongest of the intermolecular (non-covalent) interactions, about 20–40 kJ/mol. p.14 两个带电荷分子之间的静电相互作用。是分子间(非共价)相互作用中最强的,约 20–40 kJ/mol。

Transient high/low electron-density regions create temporary dipoles in hydrophobic regions. Very weak (2–4 kJ/mol) and drop off rapidly with distance, so the drug must sit close to the binding region; individually weak but very frequent. p.15 疏水区域中瞬时的高/低电子密度区产生临时偶极。非常弱(2–4 kJ/mol),且随距离迅速衰减,因此药物必须紧贴结合区域;单次作用弱但发生频繁。

Arise when both the drug and the binding site carry permanent dipole moments. Dipole alignment orients the molecule in the binding site; with distance they decay faster than ionic but slower than van der Waals forces. p.16 当药物与结合位点都具有永久偶极矩时产生。偶极排列决定分子在结合位点的取向;随距离衰减快于离子作用、但慢于范德华力。

Between a charged/ionic group of one molecule and the dipole moment of another. Stronger than dipole-dipole and decays less rapidly with distance. p.17 一个分子的带电/离子基团与另一分子偶极矩之间的作用。强于偶极-偶极作用,且随距离衰减更慢。

Between two aromatic/heteroaromatic rings, on the order of 10 kJ/mol — higher than van der Waals. Rings are generally parallel (face-to-face) or T-shaped (edge-to-face). p.18 发生在两个芳香/杂芳环之间,约 10 kJ/mol,高于范德华力。两环通常呈平行(面对面 face-to-face)或 T 形(边对面 edge-to-face)取向。

Non-covalent forces Generated by GPT-Image-2.6 Sunburst
非共价作用力 Non-covalent forces
3.3

Desolvation and the hydrophobic effect 去溶剂化与疏水效应

本节覆盖 slides 19–20

Polar regions of drug and target are solvated before interacting; removing this water shell (desolvation) requires energy. The stabilization energy gained from binding must exceed the desolvation energy penalty. p.19 药物与靶点的极性区域在结合前处于溶剂化状态;脱去水合层(去溶剂化)需要能量。结合所获得的稳定能必须大于去溶剂化的能量代价,结合才有利。

Water forms an ordered layer next to non-solvated hydrophobic regions — a negative-entropy state. Bringing hydrophobic regions together releases the ordered water, increasing entropy and favoring binding. p.20 水分子在未溶剂化的疏水区域旁形成有序层,处于负熵状态。疏水区域结合时释放有序水分子,使熵增加,从而有利于结合。

Binding can displace water from a nonpolar ligand and pocket. Solvent reorganization contributes to the hydrophobic effect. Generated by GPT-Image-2.6 Sunburst
非极性配体进入口袋时可排出周围水分子,溶剂重排是疏水效应的来源之一。 Binding can displace water from a nonpolar ligand and pocket. Solvent reorganization contributes to the hydrophobic effect.
3.4

Hydrogen bonding 氢键

本节覆盖 slides 21–24

Strength ranges widely (7–40 kJ/mol), roughly ten times weaker than a covalent bond. H-bonds are typically 1.5–2.2 Å long versus 1.0–1.5 Å for covalent bonds. p.21 强度范围较宽(7–40 kJ/mol),约比共价键弱一个数量级。氢键键长通常为 1.5–2.2 Å,而共价键为 1.0–1.5 Å。

The greater the electron density of the acceptor heteroatom, the stronger it acts as a hydrogen-bond acceptor. p.22 受体杂原子的电子密度越高,其作为氢键受体的能力越强。

Any feature affecting the electron density of the acceptor heteroatom changes its acceptor strength. p.23 任何影响受体杂原子电子密度的因素都会改变其受体强度。

Good donors contain an electron-deficient hydrogen linked to oxygen or nitrogen. The more electron-deficient the hydrogen, the better the donor. p.24 良好的供体含有一个与氧或氮相连的缺电子氢。氢的缺电子程度越高,供体能力越强。

Hydrogen bonding Generated by GPT-Image-2.6 Sunburst
氢键 Hydrogen bonding
3.5

Covalent bonds and bond energies 共价键与键能

本节覆盖 slides 25–26

Involves sharing electrons to form electron pairs between atoms. Irreversible and the strongest bond type in drug-target binding. p.25 通过共享电子在原子间形成电子对。在药物-靶点结合中属于不可逆且最强的键合类型。

Ionic interactions 20–40 kJ/mol; π–π ~10 kJ/mol; van der Waals 2–4 kJ/mol. Use the energy ranking to judge which interactions dominate affinity and specificity. p.26 离子作用 20–40 kJ/mol;π-π 约 10 kJ/mol;范德华 2–4 kJ/mol。可借助能量排序判断哪些相互作用主导亲和力与特异性。

Covalent bonds and bond energies Generated by GPT-Image-2.6 Sunburst
共价键与键能 Covalent bonds and bond energies
Final 2023-24 · Q3
4

Molecular response

分子响应
4.1

From binding to response 从结合到响应

本节覆盖 slides 27–28

Possible outcomes: enzyme inhibition; receptor agonism (response) or antagonism (block response); ion channel opening/closing. Also: change of function in mammalian cells, and loss of function in chemotherapy. p.27 可能的结果:酶抑制;受体激动(产生响应)或拮抗(阻断响应);离子通道开放或关闭。还包括:哺乳动物细胞功能改变,以及化疗中导致的功能丧失。

Illustrates how different target classes translate binding into a cellular/therapeutic response. p.28 说明不同靶点类别如何把结合作用转化为细胞/治疗响应。

From binding to response Generated by GPT-Image-2.6 Sunburst
从结合到响应 From binding to response
Residue-level hydrogen-bond distances and pi-pi stacking for YX14 and a sulfonyl-thiazole inhibitor in the enzyme pocket. Generated by Nano Banana 2.1
YX14 与磺酰基噻唑抑制剂在酶活性口袋中的残基级氢键距离与 π-π 堆积(HIS575/GLN577/ARG1064 与 ARG51/ALA68/TYR69/TYR407)。 Residue-level hydrogen-bond distances and pi-pi stacking for YX14 and a sulfonyl-thiazole inhibitor in the enzyme pocket.
4.2

YX14 case and lecture review YX14 案例与复习

本节覆盖 slides 29–30

YX14 makes multiple contacts with residues including His575, Arg1064 and Gln577. Labeled interaction distances (e.g. 1.6, 1.7, 2.7, 3.0) indicate hydrogen bonds and other close contacts anchoring the ligand. p.29 YX14 与 His575、Arg1064、Gln577 等多个残基形成接触。标注的相互作用距离(如 1.6、1.7、2.7、3.0)对应氢键及其他锚定配体的近距离接触。

Recap: definition of medicinal chemistry, diseases and drug targets, and drug-target interactions. Be able to rank non-covalent interactions by energy and link each to its structural basis. p.30 回顾:药物化学定义、疾病与药物靶点、药物-靶点相互作用。应能按能量对非共价相互作用排序,并将每种作用与其结构基础对应。

YX14 case and lecture review Generated by GPT-Image-2.6 Sunburst
YX14 案例与复习 YX14 case and lecture review
Final 2023-24 · Q3
部分内容由 AI 辅助生成,可能存在疏漏或错误,请以课件原文为准。
没有匹配的知识点,换个关键词试试。